Author

Hannah Bergom

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Anjali Sheahan· 1 shared Beatriz GermaniD· 1 shared Deborah L. BurkhartiD· 1 shared Himisha BeltraniD· 1 shared Jagpreet N. Singh· 1 shared Justin H. HwangiD· 1 shared Kate Lawrenson· 1 shared Katherine L. MoreliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anjali Sheahan

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

Beatriz German, Jagpreet N. Singh, Marcos AdS Fonseca, Deborah L. Burkhart, Anjali Sheahan, Hannah Bergom, Katherine L. Morel, Himisha Beltran, Justin H. Hwang, Kate Lawrenson, Leigh Ellis

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

bioRxiv · Jan 31, 2024 · PreprintCancer Biology